Advertisement
Screener

Verrica Pharmaceuticals Inc. (VRCA) P/E Ratio

2.8 / 5 stars · 68/120 Roast Me

Verrica Pharmaceuticals Inc. PE Ratio

The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

  • Verrica Pharmaceuticals Inc. pe ratio for the quarter ending 2026-06-30 was -3.39, a change of -3.28 year-over-year.
  • Verrica Pharmaceuticals Inc. pe ratio for the quarter ending 2026-03-31 was -5.05, a change of 1.1 year-over-year.
  • Verrica Pharmaceuticals Inc. pe ratio for the quarter ending 2025-12-31 was -8.03, a change of -7.19 year-over-year.
  • Verrica Pharmaceuticals Inc. pe ratio for the quarter ending 2025-09-30 was -1.58, a change of 6.2 year-over-year.
  • Verrica Pharmaceuticals Inc. pe ratio for fiscal 2026 was -3.39.
  • Verrica Pharmaceuticals Inc. pe ratio for fiscal 2025 was -8.03, a change of -7.19 from fiscal 2024.
  • Verrica Pharmaceuticals Inc. pe ratio for fiscal 2024 was -0.84, a change of 45.5 from fiscal 2023.
  • Verrica Pharmaceuticals Inc. pe ratio for fiscal 2023 was -46.34, a change of -0.19 from fiscal 2022.
Available history
2018-06-30 to 2026-06-30
Data captured

Historical PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-3.39$105.56M-$31.18M
2026-03-31-5.05$90.02M-$17.83M
2025-12-31-8.03$143.61M-$17.89M
2025-09-30-1.58$41.19M-$26.01M
2025-06-30-0.1$4.91M-$48.6M
2025-03-31-6.15$405.71M-$65.99M
2024-12-31-0.84$64.25M-$76.58M
2024-09-30-7.78$661.21M-$84.99M
2024-06-30-35.6$3.1B-$86.93M
2024-03-31-31.1$2.51B-$80.74M
2023-12-31-46.34$3.1B-$67M
2023-09-30-33.83$1.63B-$48.31M
2023-06-30-103.08$2.41B-$23.43M
2023-03-31-120.34$2.72B-$22.61M
2022-12-31-46.15$1.13B-$24.49M
2022-09-30-42.71$1.2B-$28.1M
2022-06-30-12.93$530.38M-$41.01M
2022-03-31-52.57$2.24B-$42.61M
2021-12-31-71.86$2.52B-$35.08M
2021-09-30-89.31$3.44B-$38.52M
2021-06-30-85.95$3.11B-$36.17M
2021-03-31-123.19$4.16B-$33.81M
2020-12-31-68.59$2.93B-$42.69M
2020-09-30-53.6$2B-$37.35M
2020-06-30-86.24$2.84B-$32.96M
2020-03-31-92.36$2.82B-$30.55M
2019-12-31-145.26$4.1B-$28.21M
2019-09-30-135$3.8B-$28.15M
2019-06-30-106.96$2.99B-$27.96M
2019-03-31-105.75$2.78B-$26.28M
2018-12-31-101.46$2.09B-$20.65M
2018-09-30-287.88$4.18B-$14.51M
2018-06-30-509.13$5.07B-$9.96M

Annual PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-3.39$105.56M-$31.18M
2025-12-31-8.03$143.61M-$17.89M
2024-12-31-0.84$64.25M-$76.58M
2023-12-31-46.34$3.1B-$67M
2022-12-31-46.15$1.13B-$24.49M
2021-12-31-71.86$2.52B-$35.08M
2020-12-31-68.59$2.93B-$42.69M
2019-12-31-145.26$4.1B-$28.21M
2018-12-31-101.46$2.09B-$20.65M

Similar stocks

Stock NameCountryMarket CapPE Ratio
OS Therapies Inc (OSTX)United States$0.076B-2.17
iBio, Inc. (IBIO)United States$0.077B-2.94
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30
Valion Bio, Inc. (VBIO)United States$0.077B
Adicet Bio, Inc. (ACET)United States$0.078B-0.81
Lifevantage Corp (LFVN)United States$0.078B15.40
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
Cingulate Inc. (CING)United States$0.073B-2.64
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Gain Therapeutics, Inc. (GANX)United States$0.080B-4.40